Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers
Viacheslav Varachev,Olga Susova,Alexei Mitrofanov,David Naskhletashvili,George Krasnov,Anna Ikonnikova,Svetlana Bezhanova,Vera Semenova,Nadezhda Sevyan,Evgenii Prozorenko,Yulia Ammour,Ali Bekyashev,Tatiana Nasedkina
DOI: https://doi.org/10.3390/ijms252313004
IF: 5.6
2024-12-04
International Journal of Molecular Sciences
Abstract:Gliomas are a heterogeneous group of brain tumors, among which the most aggressive subtype is glioblastoma, accounting for 60% of cases in adults. Available systemic treatment options are few and ineffective, so new approaches to therapies for glioblastoma are in high demand. In total, 131 patients with diffuse glioma were studied. Paired tumor–normal samples were sequenced on the Illumina platform; the panel included 812 genes associated with cancer development. Molecular profiles in clinically distinct groups were investigated. In low-grade glioma (LGG) patients (n = 18), the most common mutations were IDH1/2 (78%), ATRX (33%), TP53 (33%), PIK3CA (17%), and co-deletion 1p/19q (22%). In high-grade glioma (HGG) patients (n = 113), more frequently affected genes were CDKN2A/B (33%), TERTp (71%), PTEN (60%), TP53 (27%), and EGFR (40%). The independent predictors of better prognosis were tumor grade and IDH1/2 mutations. In IDH—wildtype glioblastoma patients, a history of other precedent cancer was associated with worse overall survival (OS), while re-operation and bevacizumab therapy increased OS. Also, among genetic alterations, TERTp mutation and PTEN deletion were markers of poor prognosis. Nine patients received molecular targeted therapy, and the results were evaluated. The search for molecular changes associated with tumor growth and progression is important for diagnosis and choice of therapy.
biochemistry & molecular biology,chemistry, multidisciplinary